Full-Time

Account Executive

Hospital Laboratory & Clinical Sales

Deadline 6/5/27
Meridian Bioscience

Meridian Bioscience

501-1,000 employees

Develops and distributes diagnostic test kits

No salary listed

Miami, FL, USA + 1 more

More locations: Sarasota, FL, USA

In Person

Applicants must reside in the assigned territory; travel by air or car is required 50% of the time, including possible overnight stays.

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Sales & Account Management (1)
Required Skills
Sales
Inventory Management
CRM
Word/Pages/Docs
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Meridian Bioscience

See people who can refer or advise you

Requirements
  • A Bachelor's Degree in Business, Healthcare, or Science is required.
  • At least four years of sales experience within a complex selling environment is required; laboratory diagnostics experience is preferred.
  • The candidate must live in the assigned territory.
  • The candidate must demonstrate consistent sales growth over time.
  • The candidate must have consultative, persuasive, relationship-building selling skills.
  • The candidate must have communication and presentation skills.
  • The candidate must have customer relationship management experience.
  • The candidate must be able to negotiate and execute contracts.
  • The candidate must be proficient in Excel, Word, PowerPoint, and Outlook at an intermediate level or higher.
  • The candidate must have product knowledge across all product lines.
  • The candidate must have planning, organizational, and administrative skills.
  • The candidate must be able to work collaboratively and maintain confidentiality and ethical standards.
  • The candidate must be able to travel by air or car 50% of the time.
  • The candidate must be able to concentrate, analyze, and solve complex issues, work outside normal business hours when needed, maintain attendance and punctuality, and perform the stated physical tasks, including loading and unloading materials and setting up and tearing down exhibit booths.
Responsibilities
  • Organize, manage, and work the assigned territory to maximize sales revenue and profitability.
  • Maintain current business in existing accounts, identify new opportunities, and close new business within existing accounts and the assigned territory.
  • Incorporate Group Purchasing Organization, Integrated Delivery Network, National Clinical Reference Laboratory, and Local Healthcare Delivery Network strategies into territory sales and revenue growth planning.
  • Achieve the sales plan across all focus product categories.
  • Meet weekly sales call targets.
  • Develop territory growth plans, account strategies, and tactics to achieve revenue growth targets.
  • Use the customer relationship management system's monthly forecast tool to measure, track, and plan new business opportunities.
  • Collaborate with other departments to improve the customer experience, create mutually beneficial solutions, and drive sales growth.
  • Educate medical staff on product benefits and provide product demonstrations and support.
  • Maintain working relationships with distribution partners within the territory.
  • Update the customer relationship management system daily with account activities, next steps, profile information, opportunities, and key decision makers.
  • Maintain the company car, sales samples, literature, product manual, and company equipment in the required condition.
  • Take inventory of sales materials and order replacements when needed.
  • Complete and submit weekly, monthly, and quarterly reports to Sales Management.
  • Manage customer inquiries, resolve issues, and escalate matters to Sales Management when appropriate.
  • Plan territory coverage and submit itineraries to Sales Management within the specified timeframe.
  • Cover the entire territory, including possible overnight stays.
  • Maintain regular attendance and punctuality and work outside normal business hours when necessary.
Desired Qualifications
  • Laboratory diagnostics sales experience is preferred.

Meridian Bioscience develops, manufactures, markets and distributes diagnostic test kits, rare reagents, specialty biologicals and components for life science and agri-bio research. Its diagnostic products are designed for use outside the body with minimal equipment, delivering accurate and fast results to aid early diagnosis of infections and lead poisoning. The company maintains an end-to-end platform from development to distribution and holds strong positions in gastrointestinal and upper respiratory infections as well as blood lead level testing, while its products also serve as components in other diagnostics. Its goal is to improve patient well-being and reduce health care costs by providing accessible, reliable diagnostics and research materials.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cincinnati, Ohio

Founded

1977

Get referred to Meridian Bioscience

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Health Canada licensed Alethia CMV on July 14, 2026, expanding Canadian molecular sales.
  • Meridian announced IVDR certification for Alethia on February 23, 2026, unlocking European access.
  • The June 10, 2026 4bases collaboration broadens ambient-stable sequencing workflows and partner revenue.

What critics are saying

  • FDA’s December 22, 2025 warning letter targets LeadCare II manufacturing and MDR failures.
  • July 31, 2026 external audits follow; missed corrections risk FDA escalation and product restrictions.
  • Magellan Diagnostics regulatory failures threaten Meridian’s diagnostics credibility and distract management through 2028.

What makes Meridian Bioscience unique

  • Meridian’s lyophilization platform makes NGS reagents ambient-stable, cutting cold-chain dependency.
  • Alethia LAMP assays deliver molecular results in under an hour across infectious diseases.
  • Meridian spans diagnostics and life science raw materials, deepening customer relationships and cross-selling.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

8%

2 year growth

8%
Associated Press
Jul 14th, 2026
Meridian Bioscience gains Health Canada licence for rapid CMV diagnostic assay

Meridian Bioscience has received Health Canada licensing for its Alethia CMV assay, expanding its molecular diagnostic offerings in the Canadian market. The assay joins Meridian's existing Alethia menu, which includes tests for C. difficile, Group A Strep, Group B Strep, malaria, Mycoplasma, and pertussis. The Alethia platform uses LAMP technology to deliver molecular results in under an hour. The CMV assay enables early detection of congenital cytomegalovirus, which affects one in 200 babies annually. Nearly one in four women carry CMV, the most common congenital infection transmitted during pregnancy. The assay uses saliva samples for congenital CMV testing. Meridian Bioscience is a privately held life science company headquartered in Cincinnati, Ohio, serving customers in over 70 countries.

Business Wire
Jun 10th, 2026
Meridian and 4bases partner to scale cytogenetics NGS assay with ambient-stable reagents

Meridian Bioscience has partnered with 4bases to enable global deployment of KaryoSolver, a next-generation cytogenetics assay, through advanced reagent stabilisation technology. The collaboration addresses a critical barrier to scaling NGS workflows: the cold-chain requirements of conventional liquid-based library preparation solutions. Meridian's lyophilisation platform stabilises KaryoSolver's NGS library preparation components, enabling ambient-temperature shipping and storage whilst maintaining diagnostic performance. The technology eliminates refrigerated logistics, extends shelf life, and simplifies global distribution. KaryoSolver consolidates structural variant detection into a single assay with integrated analysis, delivering genomic insights within hours versus days for traditional workflows. The stabilisation breakthrough allows 4bases to expand access to comprehensive genetic diagnosis whilst reducing costs and operational complexity across international markets. Both companies will exhibit at the European Human Genetics Conference in Gothenburg this June.

4bases
Jun 10th, 2026
4bases is happy to announce a collaboration agreement with Meridian Bioscience.

4bases is happy to announce a collaboration agreement with Meridian Bioscience. Ambient-stable NGS workflows, enabled by Meridian's lyophilization expertise, expand global access to 4bases' KaryoSolver(TM), a platform for rapid structural variant analysis. The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced a collaboration with 4bases SA focused on one critical objective: expanding the accessible market and enhancing the global deployment of KaryoSolver(TM), a next-generation cytogenetics assay, through advanced assay stabilization. KaryoSolver(TM) represents a significant step forward in cytogenetics. Traditional workflows rely on multiple complementary tests, often taking days to deliver a complete picture. In contrast, KaryoSolver(TM) consolidates structural variant detection into a single assay with integrated data analysis, providing actionable genomic insights within hours. However, bringing this innovation to a global market requires overcoming a critical barrier: reagent stability. Conventional liquid-based NGS library preparation solutions are inherently limited by short shelf life, creating significant challenges across the distribution chain, including the cost and complexity of refrigerated shipping and storage that have historically restricted scalable global expansion. Meridian addressed this challenge through its advanced reagent stabilization platform, combining formulation science with optimized enzyme lyophilization technology. By stabilizing the NGS library preparation components, Meridian enabled KaryoSolver(TM) to be shipped and stored at ambient temperatures, eliminating cold-chain requirements, extending shelf life, and simplifying inventory management across the global distribution channels. In addition, lyophilization streamlines manufacturing, supporting more efficient and scalable production. "Our platform technology enabled the transition of the assay into a room-temperature stable format while preserving the performance characteristics required for molecular diagnostics," said Florent Chang-Pi-Hin, Vice President, Research and Development at Meridian Life Science. "By removing cold-chain constraints without sacrificing assay integrity, we're helping expand access to reliable testing worldwide." In this fruitful collaboration, Meridian and 4bases R&D teams joined efforts to optimize Meridian's Lyophilized NGS Enzymatic DNA Fragmentation reagents for the development of a kit to be integratied into 4bases' Oxford Nanopore Technologies workflow, ensuring reliable and efficient sample preparation within the broader assay system. "The idea behind KaryoSolver(TM) is to simplify access to comprehensive genetic diagnosis, and Meridian's expertise in stabilization has been transformative," said Fabio Grandi, COO & Co-Founder at 4bases. "Short shelf life and cold-chain requirements previously limited how far and how efficiently we could scale. With lyophilization, we can now reliably supply our global customers while simplifying logistics, reducing costs, and accelerating the adoption of KaryoSolver(TM) as a rapid, single-workflow solution for cytogenetics." Together, Meridian and 4bases are removing key barriers to advanced genomic testing, pairing breakthrough assay design with the stability, scalability, and operational efficiency required for effective global deployment. 4bases and Meridian Bioscience will both be exhibiting at the upcoming European Human Genetics Conference (ESHG) on June 13-16 in Gothenburg, Sweden, where attendees will have the possibility to learn more about the companies' collaboration and latest advances in ambient-stable next-generation sequencing workflows and cytogenetics solutions. Additional event details, including opportunities to schedule meetings with the Meridian Bioscience and 4bases teams during ESHG, can be found at https://4bases.ch and Meridian Bioscience's events page. Share:

LinkedIn
May 7th, 2025
Excited to announce a strategic investment in heva — an AI-powered… | Raches Ella | 15 comments

Excited to announce a strategic investment in heva — an AI-powered platform transforming cross-border healthcare access! ✈️🌍 India is a premier destination for medical tourism, and heva, founded by Varun & Hector is solving the fragmentation that limits its growth. To healthcare providers: heva helps you focus on delivering world-class care — while they connect you to patients globally. | 15 comments on LinkedIn

PR Newswire
Mar 6th, 2025
Meridian Bioscience Congratulates Catherine Lufkin For Receiving Pure Earth'S 2025 "Force Of Nature" Award

CINCINNATI, March 6, 2025 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, proudly congratulates Catherine Lufkin, Senior Director, Global Point of Care, on being honored with Pure Earth's 2025 "Force of Nature" Award. This prestigious recognition celebrates her leadership and dedication to advancing environmental health, particularly in the fight against lead poisoning.Lufkin is being recognized at Pure Earth's International Women's Day celebration for her unwavering commitment to ensuring access to fast, accurate blood lead testing in communities impacted by lead contamination. Her leadership has been instrumental in Meridian's partnership with Pure Earth, which has provided LeadCare® II blood lead testing technology to under-resourced communities worldwide since 2016. Her dedication to advancing lead testing was also a driving force behind Meridian winning the CDC's Lead Detect Prize, a prestigious competition that fostered the development of innovative, rapid lead detection technologies to enhance public health efforts."We are immensely proud of Catherine's achievements and this well-deserved recognition," said Tony Serafini-Lamanna, President of Meridian Bioscience Diagnostics. "Her work exemplifies our mission to improve global health through innovation and collaboration. In our ongoing partnership with Pure Earth, we remain committed to reducing lead exposure and its harmful effects on vulnerable populations."The LeadCare II system, the only CLIA-waived point-of-care blood lead testing system, is a vital tool in Pure Earth's global efforts to combat lead poisoning